KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.

Background: Triple-negative breast cancer (TNBC) is characterized by high rates of recurrence and poor overall survival. This is due, in part, to a deficiency of targeted therapies, making it essential to identify therapeutically targetable driver pathways of this disease. While epidermal growth fac...

Descripción completa

Detalles Bibliográficos

Publicado en:	Breast Cancer Research Vol. 22; no. 1; pp. 1 - 15
Autores principales:	Roberts, Melyssa S., Anstine, Lindsey J., Finke, Viviane S., Bryson, Benjamin L., Webb, Bryan M., Weber-Bonk, Kristen L., Seachrist, Darcie D., Majmudar, Parth R., Keri, Ruth A.
Formato:	research Journal Article
Publicado:	BioMed Central 6/18/2020
Acceso en línea:	Ver este registro en EBSCOhost